Cost of Nivolumab in Combination with Ipilimumab As First Line Treatment in Advanced Melanoma Across Various European Markets
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.166
https://www.valueinhealthjournal.com/article/S1098-3015(17)30500-4/fulltext
Title :
Cost of Nivolumab in Combination with Ipilimumab As First Line Treatment in Advanced Melanoma Across Various European Markets
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30500-4&doi=10.1016/j.jval.2017.08.166
First page :
A426
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
142